Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Glucobay

Glucobay
In stock
25mg · 50mg
from A$68.27
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$81.93A$68.27
A$2.28 per tablet

In brief

  • Available from pharmacies and some online suppliers; Glucobay (acarbose) is officially prescription-only (Rx) in most countries including Australia, but in practice some pharmacies or e‑shops may supply it without a prescription or receipt—check local regulations.
  • Used to treat Type 2 diabetes by reducing post‑prandial blood glucose; it is an alpha‑glucosidase inhibitor that delays digestion of complex carbohydrates in the intestine, lowering blood‑sugar spikes after meals.
  • Usual dose: start 25 mg three times daily with the first bite of each main meal, then titrate to 50 mg or 100 mg three times daily as tolerated; maximum 100 mg three times daily.
  • Form of administration: oral tablet (available commonly as 25 mg, 50 mg and 100 mg tablets).
  • Onset time: begins to act with the meal—typically within about 30–60 minutes, corresponding to the time of carbohydrate absorption.
  • Duration of action: effect lasts for the duration of meal digestion—typically several hours (around 3–6 hours); effectiveness is meal‑dependent, so it must be taken with food.
  • Alcohol warning: avoid excessive alcohol; alcohol can affect glycaemic control and liver function—use caution. If hypoglycaemia occurs while taking acarbose, do not treat with regular sugar (sucrose); use glucose (dextrose) instead.
  • The most common side effect is flatulence (very common), often accompanied by abdominal pain and diarrhoea; transient increases in liver transaminases can also occur.
  • Would you like to try glucobay without a prescription?

Basic Glucobay Information

  • INN (International Nonproprietary Name): Acarbose.
  • Brand Names Available In Australia: Not specified in the data; global brands include Precose (USA), Glucobay (EU and other markets), and generics such as Acarsafe in India.
  • ATC Code: A10BF01 — Acarbose (alpha‑glucosidase inhibitor for diabetes).
  • Forms & Dosages: Oral tablets available in 25 mg, 50 mg and 100 mg strengths.
  • Manufacturers In Australia: Not specified in the data; global supplier Bayer is a market leader and generics manufacturers include Sun Pharma, Cipla and Lupin.
  • Registration Status In Australia: Not specified in the data — check the TGA ARTG for current registration details.
  • OTC / Rx Classification: Prescription Only (Rx).

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Acarbose is prescription‑only and should be managed by a prescriber and pharmacist.

Do not use acarbose in pregnancy unless a specialist advises otherwise and documents the rationale because safety in pregnancy is not established in this data set.

The elderly may tolerate acarbose but need closer monitoring for gastrointestinal side effects and hepatic enzyme changes.

Patients with significant renal impairment (serum creatinine >2 mg/dL) must not be prescribed acarbose.

Absolute contraindications include hypersensitivity, chronic inflammatory bowel disease, colonic ulceration, partial intestinal obstruction and cirrhosis.

Relative cautions include hepatic dysfunction, low body weight (<60 kg) and frailty in older adults.

Checklist for contraindications and monitoring:

  • Confirm no history of chronic inflammatory bowel disease or intestinal obstruction.
  • Check renal function and ensure serum creatinine ≤2 mg/dL before starting.
  • Review liver function tests at baseline and during therapy if clinically indicated.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Acarbose itself does not usually cause sedation or drowsiness.

Combined therapy with insulin or sulfonylureas can cause hypoglycaemia, which does impair driving and workplace performance.

Australian drivers with recurrent hypoglycaemia must follow the Australian medical standards for licensing and should notify their treating clinician when required.

Responsibilities and when to avoid driving:

  • Avoid driving if you feel hypoglycaemic symptoms such as sweating, shakiness, confusion or faintness.
  • Avoid driving during severe gastrointestinal upset if that causes dizziness or inability to concentrate.
  • Discuss fitness‑to‑drive with the prescriber if you have recurrent hypoglycaemia while using insulin, sulfonylureas or acarbose combinations.

Q&A — Can I Drive After Taking It In Australia?

Acarbose alone rarely causes drowsiness.

Do not drive if you experience severe gastrointestinal symptoms or any hypoglycaemia.

If you are using insulin or sulfonylureas alongside acarbose, always carry a source of pure glucose (dextrose) because ordinary sugar may not work effectively.

Checklist: keep dextrose on hand, test blood glucose before driving if you use insulin or secretagogues, and report recurrent hypoglycaemia to your clinician.

INN, Brand Names Available In Australia

The International Nonproprietary Name is acarbose.

Global brand names in the data include Precose and Glucobay, with generics like Acarsafe listed in other markets.

Local Australian brand availability is not specified in the source data and should be confirmed with the TGA ARTG or local suppliers.

Legal Classification (TGA Approval, PBS Listing)

Acarbose is classified as Prescription Only (Rx) in the provided data.

Check the Therapeutic Goods Administration (TGA) Australian Register of Therapeutic Goods (ARTG) for up‑to‑date registration status before supply.

PBS listing and subsidy status can change, so consult the PBS website for current subsidy details and restrictions.

INN Common Brands Strengths
Acarbose Precose; Glucobay; generics (e.g. Acarsafe) 25 mg, 50 mg, 100 mg
  • Before supply: confirm TGA ARTG registration and product sponsor.
  • Before supply: confirm current PBS status and any authority or restriction requirements.
  • Before supply: ensure a valid prescription is presented; e‑prescriptions and telehealth scripts are commonly accepted by major chains.

Standard Regimens (PBS Reference Dosing)

Typical adult dosing for Type 2 diabetes begins at 25 mg three times daily with the first bite of each main meal.

Titrate to 50 mg then 100 mg three times daily as tolerated.

The maximum recommended dose is 100 mg three times daily.

Titration checklist:

  • Start 25 mg tds with first bite of each main meal.
  • Assess gastrointestinal tolerance over 2–4 weeks before increasing dose.
  • Increase stepwise to 50 mg tds then 100 mg tds if tolerated and needed for control.

Adjustments For Comorbidities

Acarbose is not established for patients under 18 years of age.

Elderly patients do not have specific dose reductions but require monitoring for GI side effects and liver enzymes.

Avoid acarbose in significant renal impairment where serum creatinine >2 mg/dL.

Caution in hepatic dysfunction and in patients weighing <60 kg because of increased risk of transaminase changes.

Monitoring checklist:

  • Baseline and periodic LFTs if liver disease or symptoms suggest hepatic injury.
  • Baseline renal function check and repeat where clinically indicated.
  • Review gastrointestinal tolerability and adherence during titration.

Q&A — What If I Miss A Dose?

If you miss a dose, take the tablet with the next main meal when you remember it.

Do not double the next dose to make up for the missed dose.

Do not take acarbose between meals because it must be present at the first bite to work.

If several doses are missed, resume the usual schedule with the next main meal and contact your prescriber if unsure.

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Acarbose blocks enzymes that digest complex carbohydrates and is effective only when taken at the first bite of a meal.

Timing with the first bite is essential for action on postprandial glucose peaks.

Alcohol itself does not directly interact with acarbose but can increase hypoglycaemia risk if combined with insulin or sulfonylureas.

Typical Australian meals high in bread, biscuits or takeaway carbohydrates can accentuate postprandial spikes and change expected response to acarbose.

Recommendation Example
Take with first bite of meals Start tablet when placing first forkful of cereal, toast or rice in mouth.
Prefer lower‑GI carbs where possible Wholegrain bread, baked beans in moderation, avoid high‑sugar snacks.
Alcohol caution Limit alcohol if using insulin/secretagogues; ensure carbohydrate knowledge and monitoring.

Common Drug Conflicts

Direct pharmacokinetic interactions with acarbose are limited because systemic absorption is minimal.

Clinical interactions are important with insulin and sulfonylureas due to increased hypoglycaemia risk.

Do not treat hypoglycaemia with ordinary sucrose while on acarbose — use pure glucose (dextrose) instead.

Drug Effect Clinical Action
Insulin Increased hypoglycaemia risk Advise glucose monitoring; carry dextrose; consider dose adjustments.
Sulfonylureas Increased hypoglycaemia risk Educate patient on hypoglycaemia signs and pure glucose treatment.
Drugs Affecting Gut Motility Potential additive GI effects Monitor for diarrhoea, bloating; review concomitant medicines.

User Reports & Trends (Australia)

Australian patient feedback sources commonly report gastrointestinal side effects as the main issue with acarbose use.

ProductReview entries, online diabetes forums and pharmacy consultations highlight flatulence, bloating and dose‑dependent diarrhoea.

Some users report improved postprandial glucose readings when titration and dietary adjustments are followed.

  • “Lots of wind and bloating initially; got better after slow increases.”
  • “Lower post‑meal readings but had to stop because of diarrhoea.”
  • “Pharmacist advised smaller portions and wholegrain swaps — that helped.”
Sentiment Frequency Common Advice From Pharmacists
Negative (GI effects) Common Slow titration and dietary counselling.
Positive (postprandial control) Occasional Assess combination therapy and monitoring.
Access concerns Moderate in rural areas Use telehealth or local pharmacy liaison.

Adherence barriers include gastrointestinal discomfort and the need to time doses with meals, and suggested interventions are slow titration, diet adjustment and referral to a diabetes educator.

National Chains (Chemist Warehouse, Priceline, TerryWhite)

Major pharmacy chains in Australia commonly accept e‑prescriptions and telehealth scripts.

Availability of branded versus generic acarbose varies by store and region, so check stock before patient counselling.

For cost‑sensitive patients, comparing generics and PBS subsidy status is recommended.

Online Pharmacies & Telehealth E‑Prescriptions

Where to get a prescription: GP, diabetes clinic or telehealth consultation.

E‑prescriptions are commonly accepted by national chains and accredited online pharmacies, with mail‑order options for rural patients.

Checklist for safe online purchase:

  • Verify the prescriber is AHPRA‑registered.
  • Confirm the pharmacy is accredited and requires a valid prescription.
  • Check product strength and packaging before purchase.

In our online pharmacy, glucobay is available without a prescription, with discreet delivery to Australia in 9-21 days.

Safety note: do not purchase unprescribed or imported products without professional oversight; confirm tablet strengths (25/50/100 mg).

Simplified Explanation

Acarbose is an alpha‑glucosidase inhibitor that delays the intestinal breakdown of carbohydrates.

By slowing carbohydrate digestion it reduces postprandial glucose peaks after meals.

Take the tablet at the first bite so the drug is present when dietary carbohydrates arrive in the gut.

  • Alpha‑glucosidase inhibitor: blocks enzymes that digest complex carbs.
  • Postprandial glucose: primary target for glucose lowering.
  • Taken three times daily with meals for effect.

Clinical Terms

Systemic absorption of acarbose is minimal and most activity is local in the gastrointestinal tract.

Clinical benefit is modest for HbA1c but more pronounced for lowering post‑meal glucose excursions.

Pharmacology highlights: oral route, local GI effect, dose‑related transient transaminase elevations reported in some patients.

  • Minimal systemic exposure — lowers systemic drug‑drug interaction risk.
  • Monitor LFTs if clinically indicated because transaminase increases can occur.
  • Useful as add‑on therapy where postprandial control is the primary issue.

Approved Indications By TGA

The primary indication in the provided data is as adjunctive therapy for Type 2 diabetes to reduce postprandial hyperglycaemia.

Use can be as monotherapy or in combination with metformin, insulin or sulfonylureas as clinically appropriate.

  • Adjunct to diet and exercise for Type 2 diabetes to improve post‑meal glucose control.
  • Individualise therapy duration based on glycaemic targets and tolerability.

Off‑Label Uses In Australian Clinical Practice

Off‑label use is limited and should be reserved for cases where postprandial control is dominant and other agents are unsuitable.

Evidence for off‑label indications is weaker and clinicians should document the rationale and obtain informed consent.

Off‑label decision checklist:

  • Review the evidence and document expected benefit over alternatives.
  • Counsel the patient on potential adverse effects and monitoring plan.
  • Arrange follow‑up to assess efficacy and tolerability.

Key Clinical Findings (Evidence Summary)

Clinical trials and regulatory labels indicate acarbose reduces postprandial glucose and gives modest HbA1c reductions.

Gastrointestinal adverse effects are common, with flatulence reported in up to around 77% in some studies.

Transient, dose‑related increases in liver transaminases have been reported and are usually reversible.

Endpoint Effect Size / Note Main Adverse Event
Postprandial Glucose Reduction in post‑meal peaks (modest) Flatulence, bloating
HbA1c Small reductions vs baseline Diarrhoea at higher doses
Liver Enzymes Transient, dose‑related elevations reported Usually reversible on discontinuation

Monitoring endpoints: HbA1c, fasting and postprandial glucose, LFTs if indicated, and GI symptoms during titration.

PBS‑Listed Alternatives Comparison Table

Drug ATC Availability Likely PBS Status Pros Cons
Miglitol (Glyset) A10BF02 Available in some markets Confirm PBS listing Same MOA as acarbose Similar GI side effects
Meglitinides A10BX Widely available Some listed on PBS Targets postprandial insulin secretion Hypoglycaemia risk
DPP‑4 Inhibitors A10BH Available, many PBS listings Often PBS subsidised Well tolerated, low hypoglycaemia risk Less effect specifically on postprandial peaks

Pros And Cons Checklist

  • Advantages: local gut action, low systemic exposure, helpful for postprandial spikes.
  • Disadvantages: high incidence of GI side effects, requires slow titration, modest HbA1c benefit.
  • Consider cost, PBS subsidy and comorbidities (renal, hepatic) when choosing alternatives.

Common Questions (Pharmacy Consultations)

  • Will It Cause Weight Gain? — Generally weight‑neutral according to clinical summaries.
  • How Fast Will I See Effect? — Postprandial glucose falls quickly; HbA1c improvements take months.
  • What To Do For Side Effects? — Slow the dose increase, review diet, consider dose reduction or switch if severe.

Communication tips: use plain language, visual aids for timing with meals, and supply a written summary that includes hypoglycaemia treatment with dextrose.

At dispensing provide: patient leaflet, advice to carry dextrose sachets, and arrange follow‑up monitoring.

Price & Access Comparison Table

Supplier Brand/Generic Strengths Stocked Typical Price Range (AUD) PBS Subsidy Prescription Required
Chemist Warehouse Generic/Branded 25/50/100 mg (varies) Varies by brand Confirm on PBS Yes
Priceline Generic/Branded 25/50/100 mg (varies) Varies by brand Confirm on PBS Yes
Independent Pharmacy Generic/Branded May require order Varies Confirm Yes

Access checklist: verify prescription, check PBS concession benefits, consider generic alternatives for cost savings and allow mail‑order for remote patients.

TGA Approval

Clinicians and pharmacists should verify the current registration on the TGA ARTG before prescribing or dispensing.

International approvals such as FDA (Precose) and EMA (Glucobay) provide supportive safety data but Australian ARTG status determines local use.

  • Where to check: TGA ARTG, PBS schedule and sponsor information pages.
  • Confirm product‑specific indications and datasheet wording before citing label claims.

PBS Subsidy Details

PBS listings and restrictions change and must be confirmed at the time of prescribing for cost‑sensitive patients.

Check authority requirements, concession pricing and whether a specific brand or generic is subsidised.

Prescribing checklist for cost‑sensitive patients: confirm PBS listing, consider generic alternatives, and document any authority numbers required.

Household Storage In Australian Climate (Heat/Humidity)

Store acarbose tablets at around 25°C with permitted excursions between 15–30°C and protect from humidity.

In hot Australian summers avoid leaving tablets in parked cars, gloveboxes or direct sunlight.

Keep medication in original packaging, away from bathrooms and humid areas.

  • Travel tip: keep tablets in carry bags with temperature protection; avoid exposure to high heat.
  • Do not store in the bathroom due to steam and humidity.

Cold‑Chain Handling For Pharmacies

Acarbose does not require cold‑chain storage and standard ambient dispensary conditions are appropriate.

Pharmacies in hot regions should monitor storeroom temperatures and maintain temperature logs for large stock holdings.

Storage Condition Action
15–30°C ambient Store in dry dispensary area away from heat sources.
Short‑dated stock Rotate stock and notify purchasing for replenishment.
Returns Quarantine and follow local disposal procedures.

Australian Pharmacist Counselling Style

Counselling should be conversational, plain and focused on practical steps for safe use of acarbose for type 2 diabetes tablets.

Explain dosing timing clearly: first bite of each main meal, starting low and slow to reduce GI effects.

Confirm concomitant antidiabetics and discuss hypoglycaemia risk and pure glucose treatment.

  • Provide a written dose schedule and visual aid for meal timing.
  • Advise carrying dextrose sachets and a blood glucose meter where appropriate.
  • Arrange review in 2–4 weeks to assess tolerability and effect.

Patient Advice From PBS And National Health Authorities

Align counselling with national guidelines: emphasise that acarbose is an adjunct to diet, exercise and monitoring.

Advise patients to report severe adverse events and to seek review for persistent GI symptoms or signs of hepatic injury.

At dispensing, hand the patient a checklist that includes dose timing, hypoglycaemia treatment with dextrose, and when to contact their prescriber.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Townsville Queensland 14-21 days
Cairns Queensland 14-21 days

Related products